/
NVAX
$9.36+$0.48 (+5.41%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.5B
164M shares
52-week range
$6.20 – $11.97
55% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.46%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-202.95
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.3M | $18.7M | $22.4M | $197.6M | $1.60B | $556.4M | $682.2M | $1.12B |
| Cost of revenue | $0 | $113.8M | $0 | $0 | $902.6M | $343.8M | $202.7M | $71.1M |
| Gross profit | $34.3M | −$95.2M | $22.4M | $197.6M | $696.3M | $212.6M | $479.4M | $1.05B |
| Gross margin | 100.0% | -510.0% | 100.0% | 100.0% | 43.5% | 38.2% | 70.3% | 93.7% |
| R&D | $173.8M | $113.8M | $747.0M | $2.53B | $1.24B | $737.5M | $391.2M | $336.8M |
| Operating income | −$173.9M | −$120.6M | −$416.7M | −$1.69B | −$644.7M | −$566.5M | −$248.9M | $563.3M |
| EBITDA | −$163.0M | −$113.3M | −$398.2M | −$1.68B | −$604.7M | −$487.4M | −$108.0M | $492.3M |
| Net income | −$184.7M | −$130.1M | −$418.3M | −$1.74B | −$657.9M | −$545.1M | −$187.5M | $440.3M |
| Net margin | -538.8% | -697.1% | -1868.2% | -882.5% | -41.1% | -98.0% | -27.5% | 39.2% |
| EPS (diluted) | -9.99 | -5.40 | -7.43 | -23.44 | -8.42 | -5.41 | -1.23 | 2.54 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $410M | $-0.47 | $-2.09–$1.29 | 8 |
| 2027 | $257M | $-0.27 | $-0.64–$0.01 | 7 |
| 2028 | $349M | $0.55 | $-0.38–$1.17 | 6 |
| 2029 | $405M | $0.85 | $0.49–$1.26 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Novavax Inc
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
www.novavax.com- Employees
- 749
- IPO / List date
- Dec 5, 1995
- HQ
- GAITHERSBURG, MD
Held by traders on TradeandTell
No one on the platform currently holds NVAX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 497,383 | $4.0M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2019-05-10 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded NVAX yet.
